Po-Hong Liu1, Chia-Yang Hsu2, Cheng-Yuan Hsia3, Yun-Hsuan Lee1, Yi-Hsiang Huang4, Chien-Wei Su1, Fa-Yauh Lee1, Han-Chieh Lin1, Teh-Ia Huo5. 1. Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. 2. Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA. 3. Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. 4. Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. 5. Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan. Electronic address: tihuo@vghtpe.gov.tw.
Abstract
BACKGROUND AND AIMS: The survival of hepatocellular carcinoma (HCC) patients is heterogeneous. We aim to develop and validate a simple prognostic model to estimate survival for HCC patients (MESH score). METHODS: A total of 3182 patients were randomised into derivation and validation cohort. Multivariate analysis was used to identify independent predictors of survival in the derivation cohort. The validation cohort was employed to examine the prognostic capabilities. RESULTS: The MESH score allocated 1 point for each of the following parameters: large tumour (beyond Milan criteria), presence of vascular invasion or metastasis, Child-Turcotte-Pugh score ≥6, performance status ≥2, serum alpha-fetoprotein level ≥20 ng/ml, and serum alkaline phosphatase ≥200 IU/L, with a maximal of 6 points. In the validation cohort, significant survival differences were found across all MESH scores from 0 to 6 (all p < 0.01). The MESH system was associated with the highest homogeneity and lowest corrected Akaike information criterion compared with Barcelona Clínic Liver Cancer, Hong Kong Liver Cancer (HKLC), Cancer of the Liver Italian Program, Taipei Integrated Scoring and model to estimate survival in ambulatory HCC Patients systems. The prognostic accuracy of the MESH scores remained constant in patients with hepatitis B- or hepatitis C-related HCC. The MESH score can also discriminate survival for patients from early to advanced stages of HCC. CONCLUSIONS: This newly proposed simple and accurate survival model provides enhanced prognostic accuracy for HCC. The MESH system is a useful supplement to the BCLC and HKLC classification schemes in refining treatment strategies.
RCT Entities:
BACKGROUND AND AIMS: The survival of hepatocellular carcinoma (HCC) patients is heterogeneous. We aim to develop and validate a simple prognostic model to estimate survival for HCC patients (MESH score). METHODS: A total of 3182 patients were randomised into derivation and validation cohort. Multivariate analysis was used to identify independent predictors of survival in the derivation cohort. The validation cohort was employed to examine the prognostic capabilities. RESULTS: The MESH score allocated 1 point for each of the following parameters: large tumour (beyond Milan criteria), presence of vascular invasion or metastasis, Child-Turcotte-Pugh score ≥6, performance status ≥2, serum alpha-fetoprotein level ≥20 ng/ml, and serum alkaline phosphatase ≥200 IU/L, with a maximal of 6 points. In the validation cohort, significant survival differences were found across all MESH scores from 0 to 6 (all p < 0.01). The MESH system was associated with the highest homogeneity and lowest corrected Akaike information criterion compared with Barcelona Clínic Liver Cancer, Hong Kong Liver Cancer (HKLC), Cancer of the Liver Italian Program, Taipei Integrated Scoring and model to estimate survival in ambulatory HCC Patients systems. The prognostic accuracy of the MESH scores remained constant in patients with hepatitis B- or hepatitis C-related HCC. The MESH score can also discriminate survival for patients from early to advanced stages of HCC. CONCLUSIONS: This newly proposed simple and accurate survival model provides enhanced prognostic accuracy for HCC. The MESH system is a useful supplement to the BCLC and HKLC classification schemes in refining treatment strategies.
Authors: Adam Swersky; Laura Kulik; Aparna Kalyan; Karen Grace; Juan Carlos Caicedo; Robert J Lewandowski; Riad Salem Journal: Semin Intervent Radiol Date: 2021-10-07 Impact factor: 1.780
Authors: Sophia Heinrich; Martin Sprinzl; Irene Schmidtmann; Elena Heil; Sandra Koch; Carolin Czauderna; Bernd Heinrich; Laurence Philippe P Diggs; Marcus-Alexander Wörns; Roman Kloeckner; Peter R Galle; Jens U Marquardt; Arndt Weinmann Journal: United European Gastroenterol J Date: 2020-01-29 Impact factor: 4.623
Authors: Claudia Campani; Alessandro Vitale; Gabriele Dragoni; Umberto Arena; Giacomo Laffi; Umberto Cillo; Edoardo G Giannini; Francesco Tovoli; Gian Ludovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Rodolfo Sacco; Giuseppe Cabibbo; Andrea Mega; Maria Guarino; Antonio Gasbarrini; Gianluca Svegliati-Baroni; Francesco Giuseppe Foschi; Elisabetta Biasini; Alberto Masotto; Gerardo Nardone; Giovanni Raimondo; Francesco Azzaroli; Gianpaolo Vidili; Maurizia Rossana Brunetto; Fabio Farinati; Franco Trevisani; Fabio Marra Journal: Liver Cancer Date: 2021-03-17 Impact factor: 11.740
Authors: Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Alberto Masotto; Franco Trevisani Journal: J Integr Oncol Date: 2016-09-05